General Toxicity Notes
Headache, edema, flushing, dizziness.
Half-Life (Normalesrd) Hours
8/10-11
Plasma Protein Binding %
97
Volume Of Distribution L/Kg
3-4
Dose For Normal Renal Function
2.5-5 mg q12-24h
Adjustment For Renal Failure Gfr, Ml/Min >50 [Recommended Level]
100% [A]
Adjustment For Renal Failure Gfr, Ml/Min 10-50 [Recommended Level]
100% [A]
Adjustment For Renal Failure Gfr, Ml/Min <10 [Recommended Level]
100% [A]
Supplement For Dialysis [Recommendation Level]: Ihd
IHD: None
Supplement For Dialysis [Recommendation Level]: Pd
PD: None
Supplement For Dialysis [Recommendation Level]: Crrt
CRRT: Dose for GFR 10-50,titrate, [D]
References
Brogden RN, Sorkin EM. Isradipine. An update of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the treatment of mild to moderate hypertension. Drugs. 1995; 49: 618-49. [PMID: 7789292] / Chandler MH, Schran HF, Cutler RE, Smith AJ, Gonasun LM, Blouin RA. The effects of renal function on the disposition of isradipine. J Clin Pharmacol. 1988; 28: 1076-80. [PMID: 2977394] / Fitton A, Benfield P. Isradipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cardiovascular disease. Drugs. 1990; 40: 31-74.[PMID: 2143980]
Toxicity Notes
May increase digoxin levels. Bioavailability is increased in patients with impaired renal function.